Projected Income Statement: Regeneron Pharmaceuticals, Inc.

Forecast Balance Sheet: Regeneron Pharmaceuticals, Inc.

Forecast Balance Sheet - Regeneron Pharmaceuticals, Inc.
Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
Net Debt 1 -9,833 - -8,862 -6,308 -5,899 -7,168 -12,517 -17,564
Change - - - 28.82% 6.48% -21.51% -74.62% -40.32%
Announcement Date 2/4/22 2/3/23 2/2/24 2/3/25 1/30/26 - - -
1USD in Million
Estimates

Cash Flow Forecast: Regeneron Pharmaceuticals, Inc.

Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
CAPEX 1 551.9 590.1 718.6 755.9 898.4 1,106 1,122 1,140
Change - 6.92% 21.78% 5.19% 18.85% 23.11% 1.45% 1.64%
Free Cash Flow (FCF) 1 6,529 4,425 3,875 3,665 4,080 7,076 7,238 8,182
Change - -32.23% -12.42% -5.44% 11.35% 73.4% 2.29% 13.06%
Announcement Date 2/4/22 2/3/23 2/2/24 2/3/25 1/30/26 - - -
1USD in Million
Estimates

Forecast Financial Ratios: Regeneron Pharmaceuticals, Inc.

Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028

Profitability

        
EBITDA Margin (%) 61.19% 49.79% 42.29% 40.1% 37.84% 45.35% 46.39% 44.95%
EBIT Margin (%) 55.67% 46.98% 39.08% 36.7% 34.05% 42.74% 41.07% 42.59%
EBT Margin (%) 58.03% 39.91% 32.01% 33.66% 36.47% 38.25% 41.16% 41.21%
Net margin (%) 50.25% 35.64% 30.14% 31.07% 31.41% 34.16% 32.53% 33.21%
FCF margin (%) 40.63% 36.35% 29.54% 25.8% 28.45% 37.61% 35.89% 37.66%
FCF / Net Income (%) 80.86% 101.99% 98.02% 83.05% 90.58% 110.1% 110.33% 113.4%

Profitability

        
ROA 37.91% 18.9% 16.2% 15.02% 12.48% 15.29% 15.28% 15.33%
ROE 54.21% 24.93% 20.74% 19.23% 16.13% 21.87% 17.8% 17.3%

Financial Health

        
Leverage (Debt/EBITDA) - - - - - - - -
Debt / Free cash flow - - - - - - - -

Capital Intensity

        
CAPEX / Current Assets (%) 3.43% 4.85% 5.48% 5.32% 6.26% 5.88% 5.56% 5.25%
CAPEX / EBITDA (%) 5.61% 9.74% 12.95% 13.27% 16.55% 12.96% 11.99% 11.68%
CAPEX / FCF (%) 8.45% 13.34% 18.54% 20.63% 22.02% 15.63% 15.5% 13.94%

Items per share

        
Cash flow per share 1 63.11 44.18 40.4 38.41 45.85 82.34 70.83 73.8
Change - -29.99% -8.55% -4.95% 19.37% 79.59% -13.98% 4.19%
Dividend per Share 1 - - - - 3.52 3.78 4.016 4.269
Change - - - - - 7.39% 6.24% 6.29%
Book Value Per Share 1 177.6 211.6 241.4 272 298.8 350.1 397.4 455.8
Change - 19.18% 14.07% 12.7% 9.84% 17.16% 13.52% 14.69%
EPS 1 71.97 38.22 34.77 38.34 41.48 59.27 62.12 67.05
Change - -46.89% -9.03% 10.27% 8.19% 42.89% 4.81% 7.94%
Nbr of stocks (in thousands) 104,556 106,802 106,347 107,590 102,599 100,348 100,348 100,348
Announcement Date 2/4/22 2/3/23 2/2/24 2/3/25 1/30/26 - - -
1USD
Estimates
2026 *2027 *
P/E 15.5x 14.8x
PBR 2.63x 2.32x
EV / Sales 4.53x 3.96x
Yield 0.41% 0.44%

EPS & Dividend

EPS & Dividend - Regeneron Pharmaceuticals, Inc.


Y-o-Y evolution of P/E

Valuation ratios - P/E - Regeneron Pharmaceuticals, Inc.
 

Year-on-year evolution of the Yield

Valuation ratios - Yield - Regeneron Pharmaceuticals, Inc.
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Regeneron Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
920.69USD
Average target price
991.00USD
Spread / Average Target
+7.64%
  1. Stock Market
  2. Stocks
  3. REGN Stock
  4. Financials Regeneron Pharmaceuticals, Inc.
BLACK FRIDAY -Get 40% off all subscriptions
BLACK FRIDAY40% off all subscriptions
Get the offer